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Maternal and newborn deaths due to 
pre-eclampsia and eclampsia (PE/E) are 
preventable, yet in Nigeria, this is the most 
significant direct cause of maternal deaths. 
THE PROBLEM
Despite global efforts to reduce preventable maternal and 
neonatal mortality, Nigeria’s maternal mortality ratio is 
estimated at 576 deaths per 100,000 live births and neonatal 
death is estimated at 37 per 1,000 live births.
In Nigeria, hypertensive disorders in pregnancy (including 
PE/E) is the most common cause of maternal mortality, 
contributing to 29% of maternal deaths. As a major killer 
of pregnant women, greater uptake of effective, low-cost 
interventions to prevent, detect, and treat PE/E is needed at 
primary health care facilities. 
The World Health Organization (WHO) recommends 
magnesium sulphate (MgSO4) as the most effective, safe, and 
low-cost drug for treating pre-eclampsia and eclampsia.  
To increase access and use of MgSO4 in Kano State, the 
Population Council trained lower-cadre health care providers in 
antenatal clinics to detect pre-eclampsia early and instituted 
timely and appropriate management by administering the 
loading dose of MgSO4 and referring for follow up care. This 
intervention, supported by the John D. and Catherine T. 
MacArthur Foundation, reduced the maternal mortality rate 
due to PE/E by 40% in project sites. 
APPROACH 
In preparation for the study, the Council engaged with 
stakeholders and advocated for the adoption of protocols 
allowing primarily health care providers to administer the 
intramuscular (IM) loading dose of MgSO4 to women with 
severe pre-eclampsia and eclampsia prior to referral to a 
higher level facility. To gain acceptance of the proposed 
intervention, the Council worked closely with representatives 
from the Federal Ministry of Health and with community 
gatekeepers, such as traditional leaders and social workers. 
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PE/E IN BRIEF
• Pre-eclampsia is a condition               
in pregnant women marked by an 
increase in blood pressure and 
protein in urine after 20 weeks 
gestation.
• Providing high quality antenatal care 
improves the prevention and early 
detection of pre-eclampsia and can 
prevent its progression to eclampsia.
• Eclampsia is a life-threatening 
condition characterized by 
convulsions in women with PE.
• Women in developing countries are 
300 times more likely to die from 
eclampsia than women in developed 
countries.
• Pre-eclampsia and eclampsia can 
be managed by administering anti-
hypertensive drugs and magnesium 
sulphate (MgSO4).
• MgSO4 is the safest and most 
effective treatment for severe pre-
eclampsia and eclampsia, and is one 
of the 13 UN Life-Saving Commodities 
for Women and Children. 
• PE/E and other hypertensive 
disorders in pregnancy increase the 
risk of pre-term births, which can 
lead to low birth weight, anemia, and 
stunting.
• Improved prevention, increased 
detection, and effective treatment 
of PE/E can prevent unnecessary 
maternal and newborn deaths.
The Population Council conducts research and delivers 
solutions that improve lives around the world. Big 
ideas supported by evidence: It’s our model for global 
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2Between 2008 and 2014, the intervention occurred 
in two phases. The first phase (2008-2011) involved 
selecting 10 secondary health facilities in Kano State. 
Once selected, the Council then trained, mentored, 
and supervised 40 providers from these facilities 
to detect and manage PE/E patients. This included 
training them to administer a loading dose of MgSO4. 
Continued mentorship consisted of monthly visits 
from trainers, and every patient with pre-eclampsia 
or eclampsia was monitored for up to six weeks after 
delivery. 
The providers then trained and mentored additional 
providers at their respective health facilities on the 
use of MgSO4, which the Council supplied to the 
facilities. Once the provided stock of MgSO4 ran out, 
the state Ministry of Health took over procurement. 
The second phase of the intervention (2012-2014) 
focused on primary health care facilities, and divided 
them into two groups – an experimental and a control. 
In the experimental group, researchers trained 
providers to administer a loading dose of MgSO4. In 
the control group, researchers did not train providers 
to use MgSO4. 
RESULTS
Results showed that lower-cadre health providers can 
reduce maternal mortality related to PE/E if trained 
FIGURE 1    Kano Model for increaseing access to MgSO4
to administer MgSO4. Prior to the study, the Council 
found maternal mortality caused by PE/E was at 15% 
in Kano. In the experimental group, it decreased to 
1.7%. In the control group, maternal deaths remained 
the same. 
SCALE UP 
The Council intends to replicate this intervention in 
other states in Nigeria to reduce maternal deaths 
related to PE/E. Moving forward, the Council will 
modify this intervention by also training providers at 
primary health care facilities to manage hypertension 
by using antihypertensive drugs and will include a 
community component to increase awareness of signs 
and symptoms and information that details where and 
when to seek treatment. 
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